Two novel staplabin analogs, SMTP-7 and -8, have been isolated from cultures of Stachybotrys microspora IFO 3001 8. Spectroscopic analyses showed that the SMTP-7molecule consisted of two identical staplabin core structures and ornithine which bridges the two partial structures. In the SMTP-8molecule, the bridging unit was lysine. At concentrations of 80-150 /xm, the two compounds caused 2-to 12-fold increase in urokinase-catalyzed plasminogen activation, fibrin binding of plasminogen, and urokinase-and plasminogen-mediated fibrinolysis. These activities of SMTP-7and -8 were two to ten times higher than those of staplabin and previously isolated SMTPs, which exerted such effects at concentrations ranging from 150 to 800um.
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These activities of SMTP-7and -8 were two to ten times higher than those of staplabin and previously isolated SMTPs, which exerted such effects at concentrations ranging from 150 to 800um.
The plasminogen/plasmin system is involved in many physiological and pathological conditions including fibrinolysis, inflammation, tissue remodeling, ovulation, tumor metastasis and tissue invasion of pathogens1~4). In this system, the zymogen, plasminogen, is proteolytically activated to plasmin by plasminogen activators, such as urokinase and tissue plasminogen activator. Circulating plasminogen with NH2-terminal Glu (Glu1-plasminogen; hereafter simply referred to as plasminogen) is a singlechain glycoprotein with multiple functional domains, which consist of an NH2-terminal peptide, five homologous kringle domains and a trypsin-like serine protease domain5).
The binding of plasminogen to fibrin and cell surfaces, which is mediated by lysine binding sites in some kringle domains, localizes fibrinolytic activity on these surfaces6). Plasminogen exhibits a tight, spiral structure due to an intramolecular interaction between a lysine residue(s) (Lys50 and/or Lys62) in the NH2-terminal peptide and the lysine binding site (or aminohexyl site) of kringle 5á"0 and some are found to be several times as active as staplabin16). In the present study, we have searched for more potent congeners and isolated two compounds, SMTP-7 and -8, which have distinct structural features (Fig. 1) . The two analogs are 5-to 10-times more potent than staplabin in enhancing plasminogen-fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase-and plasminogen-mediated fibrin degradation.
Materials and Methods

Material s
Proteins and chemicals were from the following sources: 
Determination of 125I-Plasminogen Binding to Fibrin
Fibrin clots formed in a well of a 96-well tissue culture plate16'18) were washed three times with 100 jul of buffer B (the last wash was left in wells at 37°C for 60 minutes). The fibrin clot was then incubated at 37°C for 60 minutes with 50^1 of buffer C containing 50 nM 125I-plasminogen. Where indicated, 20 mM£-aminocaproic acid was included in the reaction mixture to obtain nonspecific binding values.
Subsequently, the wells were washed with buffer B (twice with 200^1, then once with 100/il), and 125I-plasminogen bound was dissolved in 50^1 of 0.2m NaOHand 2% (wt/vol) SDS at 37°C for 30 minutes. A portion (40^1) of the lysate was removed and counted for radioactivity using a /-counter.
Determination of Fibrinolytic Activity Fibrin clots were prepared as described above using 125I- fibrinogen (-2,500 cpm/jug). The clot was washed twice with 100^1 of buffer B containing 0.1% Tween 80 and once with 0.1ml of buffer B, then incubated with 0.2ml of buffer B containing 5 mg/ml of calf skin gelatin at 37°for 60 minutes19). After removing buffer, the clot was incubated at 37°C for 60 minutes with 60ji\ of buffer B containing 2.5 mg/ml gelatin, 0.01% Tween 80, 0.3 unit/ml urokinase and 100 nM plasminogen. Subsequently, a portion (30 /xl) of the mixture was removed to determine radioactivity released from the 125I-flbrin clot.
General Procedures
The UVspectrum was measured in MeOH on a model 320 spectrometer (Hitachi, Tokyo, Japan) and the IR spectrum on an IR-810 spectrometer (JASCO, Tokyo, Japan) with NaCl. The FAB-MSspectrum was taken on an SX-102A spectrometer (JEOL, Tokyo, Japan) using glycerol as a matrix. The NMR spectra were measured in DMSO-d6at 40°C on an EX-270 spectrometer (JEOL) at 270MHz (for *H) and 68MHz (for 13C 
Physico-chemical Properties and Structure Elucidation
The physico-chemical properties of SMTP-7 and -8 are summarizedin Table 1 . The two compoundswere soluble in chloroform, MeOHand DMSO. The molecular formulae were established from the NMRand HRFAB-MS spectra. The UVand IR spectra of the two compoundswere similar to those of staplabin13).
In the 13C NMR spectrum of each compound, two sets of signals corresponding to the ring structure and the 4,8-dimethyl-3,7-nonadienyl side chain of staplabin were found (Table 2 ). In the lH NMR spectrum, most of the signals for this moiety, except for signals for 4-H, 13-H2 and 25-H3, did not appear as doublets (Table 2 ). These observations suggested that the two compoundshad a pseudosymmetric structure. The !H-!H COSY, 43C-lR COSY and HMBCspectra were consistent with the notion that SMTP-7 and -8 had two (Table 2 and Fig. 2 ). From these results, the structures of SMTP-7and -8 were proposed as shown in 
Enhancement of Plasminogen Activation, Fibrin
Binding of Plasminogen and Fibrinolysis
The effects of SMTP-7and -8 on plasminogen activation were examined by determining the generation of plasmin activity using a chromogenic plasmin substrate, S-225 1. As shown in Fig. 3A , the rate of urokinase-catalyzed generation of plasmin activity was markedly elevated by SMTP-7 and -8 at concentrations higher than 75jim. The enhancement by SMTP-7 was 2-fold at approximately 80jiu and 12-fold at 150^m. SMTP-8 was less active than SMTP-7, and gave 2-and 4-fold increases at 80 and 140 /im, respectively. In control incubations in the absence of urokinase, the two compoundsshowed no effect on the plasminogen activation (data not shown). Fibrinolytic activity was determined by incubating 125I-flbrin with urokinase and plasminogen in the presence of the two compounds (Fig. 3C) . In this system, SMTP-7and -8 elevated 3-fold the 125I-flbrin degradation at 150 and 120jum, respectively. In the absence of urokinase, fibrinolysis was not elevated by the two agents, indicating that these effects were mediated by plasminogen activation.
Discussion
Two new staplabin analogs, SMTP-7, and -8 have been isolated in this study. SMTP-7 has a structure that two identical units (chromanlactam with 4,8-dimethyl-3,7-nonadienyl side chain) are bridged by ornithine.
In the SMTP-8 molecule, the bridging moiety is lysine. In the previous study, we have isolated four SMTPswith an amino acid side chain attached to the nitrogen atom of the chromanlactammoiety16). These metabolites are assumedto be formed by incorporating amino acids. Thus, the two amino groups of ornithine and lysine are likely to be similarly attacked to form two lactam ring structures of the SMTP-7 and -8 molecules. Supporting this hypothesis is the observation that the feeding S. microspora IFO 30018 with ornithine and lysine results in marked increases in the production of SMTP-7and -8, respectively (manuscript in preparation). As mentioned in the introduction, agents that relax plasminogen conformation and, hence, increase its activation and fibrin binding maybe beneficial to stimulate localyzed endogenous flbrinolytic activity. The first such candidate agent with a low molecular weight is staplabin. However, staplabin is less potent and exerts effects at concentrations of 400-800jiuUM\ On the other hand, SMTP-7 and -8 enhance several fold the urokinasecatalyzed plasminogen activation and plasminogen-fibrin binding as well as urokinase-and plasminogen-mediated fibrinolysis at concentrations of 80-150 /iM. Thus, the two analogs are 5-10 times more potent than staplabin. It is likely that these effects involve conformational relaxation ofplasminogen, since, like staplabin, SMTP-7 and -8 cause direct activation of neither plasmin nor urokinase. SMTP-7 and -8 should provide useful tools for studies of the conformational regulation of plasminogen activation as well as for the development of anti-thrombotic agents. 
